VANDA PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
VANDA PHARMACEUTICALS INC. (VNDA) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of $100.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for the quarter ending 2025-09-30 was $100.00K, a 50.00% decline year-over-year.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for the quarter ending 2025-06-30 was $400.00K, a 100.00% increase year-over-year.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for the quarter ending 2025-03-31 was $500.00K, a 0.00% change year-over-year.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for the quarter ending 2024-09-30 was $200.00K, a 0.00% change year-over-year.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 3 month | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 6 month | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 9 month |
|---|---|---|---|
| 2025-09-30 | $100.00K 10-Q · filed 2025-10-30 | $500.00K derived: sum of 2 quarters · filed 2026-08-06 | $900.00K 10-Q · filed 2025-10-30 |
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-06 | $800.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $500.00K 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $200.00K 10-Q · filed 2025-10-30 | $400.00K derived: sum of 2 quarters · filed 2025-10-30 | $1.00M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $200.00K 10-Q · filed 2025-07-31 | $800.00K 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $200.00K 10-Q · filed 2024-11-07 | $1.00M derived: sum of 2 quarters · filed 2024-11-07 | $2.10M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-01 | $1.80M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-09 | ||
| 2022-09-30 | $400.00K 10-Q · filed 2023-11-09 | $700.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.80M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $300.00K 10-Q · filed 2023-07-28 | $1.40M 10-Q · filed 2023-07-28 | |
| 2022-03-31 | $1.10M 10-Q · filed 2023-05-03 | ||
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-03 | $400.00K derived: sum of 2 quarters · filed 2022-11-03 | $200.00K 10-Q · filed 2022-11-03 |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-04 | $100.00K 10-Q · filed 2022-08-04 | |
| 2021-03-31 | -$300.00K 10-Q · filed 2022-05-06 | ||
| 2020-09-30 | $500.00K 10-Q · filed 2021-11-04 | $1.20M derived: sum of 2 quarters · filed 2021-11-04 | $1.60M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $700.00K 10-Q · filed 2021-07-29 | $1.10M 10-Q · filed 2021-07-29 | |
| 2020-03-31 | $400.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |